RecruitingPhase 4NCT07173855

Effect of Protocolized Magnesium Replacement on Mortality and Atrial Fibrillation in Critically Ill Patients

Effect of Protocolized Magnesium Replacement in Critically Ill Patients on Mortality and Atrial Fibrillation: the MAGNOLIA Randomized Controlled Trial


Sponsor

Scarborough General Hospital

Enrollment

3,253 participants

Start Date

Nov 25, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

In patients with critical illness, such as severe infections, heart attacks, or respiratory failure, most intensive care units (ICUs) measure magnesium levels and give supplemental doses of magnesium when levels are below certain targets. However, the best targets are unknown. The goal of this clinical trial is to study protocols for magnesium supplementation in people with critical illness, comparing a protocol with higher target level to a protocol with a lower target level. The main question this study aims to answer is whether magnesium supplementation protocols targeting a higher or lower level lead to better 30-day survival and less atrial fibrillation. Participants will not have to do any specific tasks, undergo any additional tests, or complete any surveys.


Eligibility

Min Age: 16 Years

Plain Language Summary

Simplified for easier understanding

This trial tests whether a structured magnesium replacement plan for ICU patients reduces the risk of death and irregular heart rhythms (atrial fibrillation). You may be eligible if... - You are 16 years or older - You have been admitted to a medical-surgical intensive care unit at a participating hospital - You have been placed on a magnesium replacement protocol You may NOT be eligible if... - You have previously enrolled in or withdrawn from this trial - You have sustained ventricular tachycardia (a dangerous fast heart rhythm) - You have pre-eclampsia (a pregnancy complication) - You have myasthenia gravis Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMagnesium sulfate administration

Magnesium sulfate is used in both arms for magnesium replacement.

DRUGMagnesium oxide

In the higher-target arm, magnesium oxide 420mg po q12h x 2 is one of the options available for magnesium replacement when magnesium levels lie between 0.75 and 0.95mmol/L.

DRUGMagnesium glucoheptonate

Magnesium glucoheptonate 30mL po q12h x 2 is an oral option for magnesium replacement in the higher-target arm.


Locations(6)

Lakeridge Health Ajax-Pickering

Ajax, Ontario, Canada

Lakeridge Health Bowmanville

Bowmanville, Ontario, Canada

Lakeridge Health Oshawa

Oshawa, Ontario, Canada

Scarborough Centenary Hospital

Toronto, Ontario, Canada

Scarborough General Hospital

Toronto, Ontario, Canada

Scarborough Birchmount Hospital

Toronto, Ontario, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07173855


Related Trials